Tuberculosis Drug Discovery and Development 2019

Tuberculosis Drug Discovery and Development 2019

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main c...

Full description

Bibliographic Details
Format: eBook
Language:English
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
Biology, life sciences
Research & information: general
anti-TB drug pipeline
anti-virulence compounds
antibiotic
antimicrobial drug resistance (AMR)
antimycobacterial
antituberculosis agents
artificial pneumothorax
BCG
bedaquiline
biomarkers
Carlo Forlanini
caseum
cell envelope
clinical studies
clinical trial
CTVD
delpazolid
discovery
DNA gyrase
dormancy
DprE1 inhibitor
drug combination
drug development
drug discovery
drug resistance
drug-drug interactions
EDCTP
electron transport chain
energy metabolism
genomics
granulomas
host-directed therapy
IAVI
in vitro
in vivo
isoniazid
lead generation
lipidomics
macozinone
mechanism of action
mechanisms of resistance
metabolomics
MID3
mode of action
multi-drug resistance
mutations
mycobacteria
mycobacterium
Mycobacterium tuberculosis
n/a
oxidative phosphorylation
pharmacodynamics
pharmacokinetics
phenotypic screening
PknB
PknG
post-treatment sequelae
privileged targets
promiscuous targets
proteomics
pulmonary rehabilitation
Q203
rifampin
structure-based drug design
surgery
target
target identification
target-based drug design
target-based screening
TB
TBVI
toxicity
transcriptomics
tuberculosis
tuberculosis treatment
tuberculosis vaccines
Online Access:Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication

Internet

Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication

Similar Items